Draegerwerk Ag & Co. Kgaa · XETR:DRW8
Draegerwerk Ag & Co. Kgaa — Drägerwerk AG & Co. KGaA — Q1 2025 Earnings Presentation
41 slides from Draegerwerk Ag & Co. Kgaa's earnings presentation, Apr 30, 2025
Slide 1: Capital Markets Presentation Drägerwerk AG & Co. KGaA
Capital Markets Presentation Drägerwerk AG & Co. KGaA April 2025, Lübeck Fußzeile: Bitte entsprechende Gesellschaft ergänzen
Slide 2: Disclaimer
Disclaimer — This presentation does not constitute an offer of securities for sale or a solicitation of an offer to purchase any securities. No money, securities or other consideration is being solicited by this presentation. This presentation contains forward-looking statements regarding the future
Slide 3: Content – Agenda
Content – Agenda — 01 Company 02 Financials 03 Outlook Drägerwerk AG & Co. KGaA 3
Slide 4: Dräger products protect, support and save lifes
„Dräger products protect, support and save lifes.“ Stefan Dräger, Chairman of the Executive Board Drägerwerk AG & Co. KGaA 4
Slide 5: Company
01 Company Drägerwerk AG & Co. KGaA 5
Slide 6: Net sales development – Long-term growth
Net sales development – Long-term growth Corona 4.000 pandemic Ukraine war 3.500 Debt 3.000 crisis Financial 2.500 crisis Stock- market 2.000 Russian crash Mexican financial 1.500 peso crisis crisis 1.000 500 0 2011 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2010 2012 2013 2014 2015 2016 2017
Slide 7: Dräger worldwide: Net sales, employees, sites
~44% ~56% Dräger worldwide Safety Division 16% 23% Medical Division Net sales, employees, sites 3.4 bn EUR net sales 22% 20241 39% ~59% ~18% Sales, Production, quality, 14% Marketing, logistics, purchasing service 16,598 14% employees 47% ~11% Research Headquarters 20241 and development Development
Slide 8: Our markets
Our markets Medical Technology Safety Technology Hospital Fire Services Oil and gas industry Mining Chemical industry Other markets Drägerwerk AG & Co. KGaA 8
Slide 9: Medical division
Medical division Operating Room Neonatal Care Intensive Care Hospital wide solutions Anaesthesiology Patient Monitoring & Clinical IT • Anaesthesia • Infinity Acute Care workstations and vaporizers • System Clincal software • #1 in Europe and solutions #2 in the US market • Telemetry and IT-
Slide 10: Safety division
Safety division Chemical Oil & Gas Mining Fire Service Other Markets Breathing Systems Impairment Check Equipment • Self-contained • Alcohol- and drug Breathing Appartus for fire fighters • screening devices Interlock devices • #2 worldwide and • #1 worldwide and #1 in Europe #1 in Europ
Slide 11: Medical and safety technology providing long-term growth prospects
Medical and safety technology providing long-term growth prospects Medical division Safety division • Average expected annual market growth for the global • Very diversified markets with numerous product and medical equipment market significantly exceeding service offerings Attractive growth prospec
Slide 12: Technology and innovation leadership to drive profitable growth
Technology and innovation leadership to drive profitable growth Strong R&D focus Innovation to enhance future growth (examples) • Approximately 1,800 employees in R&D around the globe. • EUR ~330 million spent for R&D activities in 2024.* • Very close collaboration with customers to develop new and
Slide 13: Exploit growth potentials in developing countries
Exploit growth potentials in developing countries • Focus on the specific needs of customer in developing countries Investments in profitable • Capitalize on the significant investments into the Sales & Service infrastructure and specific growth in developing market knowledge, especially in our Regi
Slide 14: Service- and consumables business a clear focus of our sales activities
Service- and consumables business a clear focus of our sales activities Further expansion of • Capitalize on large installed base to expand after sales business service and consumables • Focus on combined sale of equipment and after sales contracts business • Expansion of disposable consumables busi
Slide 15: Financials
02 Financials Drägerwerk AG & Co. KGaA 15
Slide 16: Business development Dräger Group – 5-year view
Business development Dräger Group – 5-year view Dräger Group 2020 2021 2022 2023 2024 Q1 2025 Q1 2024 € million € million € million € million € million € million € million Net sales 3,406 3,328 3,045 3,374 3,371 730 736 Change (nominal) 22.5% -2.3% -8.5% 10.8% -0.1% -0.8% -3.3% Change (net of curren
Slide 17: Key figures Dräger Group – 5-year view
Key figures Dräger Group – 5-year view Dräger Group 2020 2021 2022 2023 2024 Q1 2025 Q1 2024 Change € million € million € million € million € million € million € million % Cashflow (from operating activities) 460 385 -144 190 167 56 34 66.8 Investments 178 194 131 142 126 29 23 26.9 Cash and cash eq
Slide 18: Outlook
03 Outlook Drägerwerk AG & Co. KGaA 18
Slide 19: Outlook: Expectations for fiscal year 2025
Outlook Expectations for fiscal year 2025 Results achieved Forecast for Indicator for fiscal year 2024 fiscal year 20251 Net sales (net of currency effects) 0.5% 1.0 to 5.0% EBIT margin 5.8% 3.5 to 6.5% Dräger Value Added (DVA) EUR 54.3 million EUR -30 to 80 million 1 The potential impact of US cust
Slide 20: Outlook Mid-term Corporate
Outlook 01 02 03 Mid-term Profitability first Innovation Leadership Competence in Inter- operability/System Business Corporate Priority has changed Revitalize our innovation, deploy — from revenue growth this strength successfully to our We enhance the level of Objectives towards profitability. mark
Slide 21: Technology for Life
Technology for Life Drager
Slide 22: Outlook: Expectations for fiscal year 2025
1 Excluding company acquisitions and the capitalization of right-of-use assets pursuant to IFRS 16 Outlook Expectations for fiscal year 2025 Forecast for Current forecast for Indicator fiscal year 2024 fiscal year 20252 Net sales (net of currency effects) 0.5% 1.0 to 5.0% EBIT margin 5.8% 3.5 to 6.5
Slide 23: Management: The Dräger Executive Board
Management The Dräger Executive Board Stefan Dräger Gert-Hartwig Lescow Stefanie Hirsch Rainer Klug Dr. Reiner Piske Anton Schrofner Chairman of the Deputy Chairman of Executive Board Executive Board Executive Board Executive Board Executive Board - the Executive Board; Member for member for Safety
Slide 24: Dräger shares: Shareholder structure
Dräger shares Shareholder structure 10,160,000 Common shares (23.4% Free float) 8,600,000 Preferred shares (100.0% Free float) Freefloat 23.37% Germany USA 14% 30% Shareholding Shareholder structure 2 Rest of Europe Common shares 1 15% Rest of the world Dräger family Private 7% Brandes Investment 71
Slide 25: Business development Group / Division / Region
Business development Group / Division / Region Dräger Group 2021 2022 2023 2024 Q1 2025 Q1 2024 Change Change € million € million € million € million € million € million % nominal % fx-adj. Medical division 2,064.2 1,821.5 1,966.2 1,899.7 413.1 417.4 -1.0 -1.6 Safety division 1,264.2 1,223.7 1,407.3
Slide 26: Medical division Business development
Medical division Business development Medical division 2021 2022 2023 2024 Q1 2025 Q1 2024 Change Change € million € million € million € million € million € million % nominal % fx-adj. Net sales 2,064.2 1,821.5 1,966.2 1,899.7 413.1 417.4 -1.0 -1.6 Germany 465.1 367.5 402.7 406.8 99.2 94.8 4.7 4.7 E
Slide 27: Safety division Business development
Safety division Business development Safety division 2021 2022 2023 2024 Q1 2025 Q1 2024 Change Change € million € million € million € million € million € million % nominal % fx-adj. Net sales 1,264.2 1,223.7 1,407.3 1,471.2 317.2 318.4 -0.4 -0.6 Germany 299.0 298.0 345.6 369.0 77.4 75.2 2.9 2.9 EME
Slide 28: Functional expenses Dräger Group – 5-year view
Functional expenses Dräger Group – 5-year view Dräger Group 2020 2021 2022 2023 2024 Q1 2025 Q1 2024 Change € million € million € million € million € million € million € million % R&D 289.6 328.6 343.5 325.4 333.1 83.6 80.9 3.3 % of net sales 8.5% 9.9% 11.3% 9.6% 9.9% 11.4% 11.0% Sales & Marketing 6
Slide 29: Cash flow statement Dräger Group – 5-year view
Cash flow statement Dräger Group – 5-year view Dräger Group 2020 2021 2022 2023 2024 Q1 2025 Q1 2024 Change € million € million € million € million € million € million € million % Group net profit 249.9 154.3 -63.6 112.0 124.8 -1.9 7.5 >-100 Change in inventories -162.0 14.4 -81.8 13.0 -6.2 -60.3 -5
Slide 30: Balance sheet (assets) Group 12M
Balance sheet (assets) Group 12M Assets 12.2024 12.2023 Change € million € million % Intangible assets 342.8 345.6 -0.8 Property, plant and equipment (incl. Right-of-use-assets) 549.0 571.3 -3.9 Other noncurrent assets 316.8 305.9 3.6 Noncurrent assets 1,208.7 1,222.8 -1.2 Inventories 662.6 654.7 1.
Slide 31: Balance sheet (equity and liabilities) Group 12M
Balance sheet (equity and liabilities) Group 12M Equity and liabilities 12.2024 12.2023 Change € million € million % Equity 1,536.8 1,409.2 9.1 Provisions for pensions and similar obligations 180.4 204.6 -11.8 Noncurrent personnel provisions 36.6 35.4 3.3 Noncurrent interest bearing loans 104.4 157.
Slide 32: Business development Dräger Group – 5 years
Business development Dräger Group – 5 years — Order intake1 Net sales1 EBIT1 (margin) fx-adj. +38.9% -17.9% +2.9% +2.2% +3.4% +25.7% -1.8% -11.5% +13.1% +0.5% (11.6%) (8.2%) (-2.9%) (4.9%) (5.8%) nominal +35.4% -18.4% +6.4% +0.2% +2.8% +22.5% -2.3% -8.5% +10.8% -0.1% CAGR -2.8 % CAGR -0.3 % 3,786 39
Slide 33: Business development Dräger Group – 5 years
Business development Dräger Group – 5 years — DVA1 Equity1 (ratio) Net financial debt1 (/EBITDA) (31.3%) (39.7%) (42.5%) (45.5%) (49.7%) (0.36) (-0.06) (4.64) (0.63) (0.49) 297 1,537 1,409 1,319 259 1,260 1,034 187 198 172 165 56 54 -33 -196 -24 2020 2021 2023 2024 2020 2021 2022 2023 2024 2020 2022
Slide 34: Business development Medical division – 5 years
Business development Medical division – 5 years — Order intake1 Net sales1 EBIT1 (margin) fx-adj. +48.6% -22.6% -0.5% -1.3% +1.2% +36.0% -9.7% -15.0% +10.3% -2.7% (14.3%) (9.3%) (-5.0%) (1.9%) (1.5%) nominal +44.6% -23.3% +3.3% -3.2% +0.4% +32.2% -10.3% -11.8% +7.9% -3.4% 2,499 329 2,302 1,979 2,064
Slide 35: Business development Safety division – 5 years
Business development Safety division – 5 years — Order intake1 Net sales1 EBIT1 (margin) fx-adj. +23.3% -8.8% +8.4% +7.4% +6.4% +8.5% +14.5% -5.8% +17.2% +4.9% (6.1%) (6.3%) (0.1%) (9.2%) (11.3%) nominal +20.6% -9.1% +11.5% +5.2% +6.0% +6.3% +14.5% -3.2% +15.0% +4.5% 1,456 1,471 166 1,374 1,407 1,28
Slide 36: Dividend policy
Dividend policy Dräger intends to continue distributing at least 30% of consolidated annual net profit in the coming years, provided that the Group's equity ratio is at least 40%. — Total distribution1 (rate) Dividend (yield) per Dividend (yield) per common share2 preferred share2 (1.8%) (2.4%) (-5.
Slide 37: Sustainability Ratings
Sustainability Ratings • As in the prior year, Dräger was awarded 72 out of 100 points in 2024 in the CSR assessment of the EcoVadis institute, grouping them in the best 15% of companies assessed by EcoVadis. • In addition, Dräger once again received the “Prime Label” in ISS' ESG Corporate Rating, t
Slide 38: Silent ICU
Muting and Analgesia forwarding control alarms Gentle ventilation and weaning Patient monitoring Silent ICU • Concept for alarm forwarding and muting of medical devices with Service-oriented Device Connectivity (SDC) • Information flows bi-directionally across manufacturers with SDC • Patient device
Slide 39: Financial calendar Events
Financial calendar Events Dräger publishes preliminary results approximately 2 weeks before the dates of the quarterly reports. Preliminary results for the full year are published in January. March 31, 2025 Annual Report 2024 Conference Call April 30, 2025 Report for the first three months 2025 Conf
Slide 40: Contact
Contact Thomas Fischler | Head of Treasury & Investor Relations Moislinger Alle 53-55 23558 Lübeck, Germany Tel. +49 451 882 2685 Mail: thomas.fischler@draeger.com Nikolaus Hammerschmidt | Investor Relations Manager Moislinger Alle 53-55 23558 Lübeck, Germany Tel. +49 451 882 8903 Mail: nikolaus.ham
Slide 41: Thank you
Thank you Drägerwerk AG & Co. KGaA 41
Drägerwerk AG & Co. KGaA — Q1 2025 Earnings Presentation on 6ix